Ventyx Biosciences (VTYX) rose 5.2%, before being halted, after a report that Eli Lilly (LLY) is near a deal for the company.
Eli Lilly (LLY) is advanced talks to acquire Ventyx, which specializes in developing pills that can treat inflammatory diseases, according to a WSJ report on Tuesday, which cited people familiar with the matter. A deal could be announced imminently.
Ventyx has a market cap of $600 million.